期刊文献+

RP-HPLC-UV法测定盐酸雷诺嗪原料药及有关物质的含量

Detection of the contect of ranolzaine hydrochloride and related compounds by RP-HPLC-UV
下载PDF
导出
摘要 目的建立RP—HPLC—uV法用于盐酸雷诺嗪的含量和有关物质测定。方法采用WatersXBRIDGEC。8色谱柱(250mm×4.6mm,5μm),流动相为乙腈一20mmol·L^-1磷酸二氢钾溶液(用三乙胺调节pH值至7.0)(体积比40:60),流速为1.0mL·min^-1,检测波长为215nm,进样量为10μL。结果盐酸雷诺嗪质量浓度在9.068—226.7mg·L^-1内线性关系良好(r=0.9996),重复性试验RSD为0.96%,主峰与各杂质均具有较好的分离度。结论该方法快速、准确、专属性强,适用于盐酸雷诺嗪及其制剂的质量控制。 Objective To establish an HPLC-UV method for the detection of ranolzaine hydrochloride and re- lated compounds. Methods A Waters XBRIDGE C18 column (250 mm ×4.6mm,5μm) was used;the mo- bile phase consisted of acetonitrile-KH2PO4 solution (20 mmol. L ^-1 , adjusted to pH 7.0 with triethylamine) ( V: V=40:60) ;the flow rate was set at 1.0 mL.min^-1 and the detector was set at 215 nm with an injection volume of 10 μL. Results The linear range was 9. 068-226. 7 mg.L^-1 (r =0. 999 6). The relative standard deviation for precision was 0. 2%. The resolution between ranolazine and corresponding related substances was good. Conclusions The present method is rapid, accurate, sensitive, and suitable for the quality control of ranolazine hydrochloride and its formulations.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2013年第11期872-875,共4页 Journal of Shenyang Pharmaceutical University
关键词 盐酸雷诺嗪 含量测定 有关物质 高效液相色谱 ranolzaine hydrochloride content determination related substance HPLC
  • 相关文献

参考文献6

二级参考文献40

  • 1钟皎,柳晓泉,王永升,赵小平,陈燕,王广基.RP-HPLC法研究不同性别的大鼠尿液中盐酸雷诺嗪及其代谢物的差异[J].中国药科大学学报,2006,37(3):238-241. 被引量:10
  • 2叶亚琳,李雪,徐江平,杨雪梅.雷诺嗪的大鼠体内药物动力学研究[J].中国医药工业杂志,2006,37(7):478-480. 被引量:7
  • 3叶亚琳,杨雪梅,寻炟,徐江平.RP-HPLC测定雷诺嗪含量及有关物质[J].中国新药杂志,2006,15(14):1190-1192. 被引量:9
  • 4程靖,刘祖明,卿湘华,杨光富.高效液相色谱法测定盐酸雷诺嗪原料药的含量及有关物质[J].药物分析杂志,2006,26(11):1599-1601. 被引量:6
  • 5Tian L,Jiang J, Huang Y, et al. Sensitive quantification of ranolazine in human plasma by liquid chromatography-tandem mass spectrometry with positive elcctrospray ionization [J]. J Chromatogr B, 2007,846(1/2) :346.
  • 6Eva AC, Tibor G, Kalman H. Process for the preparation of piperazine derivatives [ P]. EP: 0483932 A1,1991 - 10- 31.
  • 7McCormack JG, Stanley WC, Wolff AA. Ranolazine, a novel metabolic modulator for the treatment of angina[J]. Gen Pharm, 1998, 30(5) :639 - 645.
  • 8Zacharowski K, Lackburn BB, Thiemeermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat [ J ]. Eur J Pharmacol, 2001, 418 (1 - 2) : 105 -110.
  • 9Mcaroon J, Clark RD, Kluge AF, et al. Synthesis and antihypertensive activity of a series of 8-aubalituted 1-oxa-3, 8-diazaspiro [ 4. 5 ] decan-2-ones [ J ]. J Med Chem, 1981,24(11) : 1320 - 1328.
  • 10Kluge AF, Clark RD, Strosberg AM, et al. Cardioselective aryloxy-and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry[P]. US:4567264,1986 - 01 - 28.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部